Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 50, Issue 7, 2004, Pages 2113-2121

  Van Gaalen, Floris A ^a   Van Aken, Jill ^a   Huizinga, Tom W J ^a   Schreuder, Geziena M Th ^a   Breedveld, Ferdinand C ^a   Zanelli, Eric ^a   Van Venrooij, Walther J ^b   Verweij, Cornelis L ^c   Toes, René E M ^a   De Vries, René R P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELISM; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOOT RADIOGRAPHY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAND RADIOGRAPHY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; EPITOPES; FEMALE; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 3142769762     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20316     Document Type: Article

References (37)

1. Seldin MF, Amos CI, Ward R, Gregersen PK. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999;42:1071-9.
2. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989;36: 178-82.
3. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
4. Wagner U, Kaltenhauser S, Sauer H, Arnold S, Seidel W, Hantzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40: 341-51.
5. Van Zeben D, Hazes JM, Zwinderman AH, Cats A, Schreuder GM, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis: results of a followup study. Arthritis Rheum 1991;34:822-30.
6. De Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum 2002;46: 921-8.
7. Zanelli E, Gonzalez-Gay MA, David CS. Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today 1995;16:274-8.
8. Van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
9. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-62.
10. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
11. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
12. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
13. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
14. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001;166:4177-84.
15. Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, et al. In the rheumatoid pannus, antifilaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000;119:544-52.
16. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van den Berg WB, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003;48:2489-500.
17. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
18. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2: 236-43.
19. Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, et al. Association of rheumatoid factors and antifilaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1082-8.
20. Van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37:1084-8.
21. Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996;55:157-61.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JM, et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002;46:899-905.
24. Van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiologic outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63:274-9.
25. Van der Heijde DM. Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-53.
26. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994;56:389-466.
27. Zanelli E, Huizinga TW, Guerne PA, Vischer TL, Tiercy JM, Verduyn W, et al. An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics 1998;48:394-401.
28. Van der Horst-Bruinsma IE, Visser H, Hazes JM, Breedveld FC, Verduyn W, Schreuder GM, et al. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999;60:152-8.
29. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
30. Hulsmans HM, Jacobs JW, van der Heijde DM, Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
31. Vos K, Visser H, Schreuder GM, de Vries RR, Zwinderman AH, Breedveld FC, et al. Human leukocyte antigen-DQ and DR polymorphisms predict rheumatoid arthritis outcome better than DR alone. Hum Immunol 2001;62:1217-25.
32. Mattey DL, Dawes PT, Clarke S, Fisher J, Brownfield A, Thomson W, et al. Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis. Arthritis Care Res 2002;47:403-7.
33. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
34. Reviron D, Perdriger A, Toussirot E, Wendling D, Balandraud N, Guis S, et al. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum 2001;44:535-40.
35. Schur PH. IgG subclasses-a review. Ann Allergy 1987;58: 89-96,99.
36. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001;44:2255-62.
37. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402.